BACKGROUND: Trachelectomy is the treatment of choice for reproductive-aged women with early-stage cervical cancer who desire future fertility. Comprehensive population-based statistics have been missing to date. OBJECTIVE: We sought to compare characteristics and survival of reproductive-aged women who underwent trachelectomy for early-stage cervical cancer to those who had hysterectomy. STUDY DESIGN: This is a retrospective observational study examining the Surveillance, Epidemiology, and End Results program from 1998 through 2014. Women <45 years of age with stage IA and IB1 (tumor size 2 cm) cervical cancer who underwent trachelectomy were compared to those who underwent hysterectomy. Multivariable models were used to identify clinicopathological factors associated with trachelectomy. Survival was compared between the 2 groups after propensity score matching. RESULTS: Among 6359 women, 190 (3.0%; 95% confidence interval, 2.6e3.4) underwent trachelectomy. The median age of the trachelectomy group was 31 years (interquartile range, 28e34). The proportion of women who underwent trachelectomy significantly increased during the study period (1.2% in 1998 through 2002, 3.0% in 2003 through 2008, and 4.5% in 2009 through 2014, P < .001). Younger age, nonblack race, single marital status, eastern registry area, recent disease diagnosis, nonsquamous histology, and higher stage were independent factors associated with trachelectomy use (all, adjusted P < .05). After propensity score matching, 5-year cause-specific survival (96.9% vs 96.6%; hazard ratio, 0.73; 95% confidence interval, 0.23e2.30; P ¼ .59) and overall survival (96.1% vs 96.6%; hazard ratio, 0.76; 95% confidence interval, 0.26e2.20; P ¼ .61) were similar between the trachelectomy group and the hysterectomy group. CONCLUSION: Our study found that there was a significant increase in the proportion of reproductive-aged women with stage IA or IB1 ( 2 cm) cervical cancer who underwent trachelectomy in recent years. Survival with trachelectomy was similar to those who had hysterectomy in this population.
Introduction
Cervical cancer remains the most common gynecologic malignancy in reproductive-aged women in the United States. 1 The American Cancer Society predicts that about 13,240 new invasive cervical cancer cases will be diagnosed in the United States in 2018, 2 and >4000 women are expected to die from the disease this year. 1 Early-stage cervical cancer generally has a favorable prognosis with either surgery or radiation. 3 Standard surgical management of earlystage cervical cancer includes simple or radical hysterectomy with or without pelvic lymphadenectomy depending on disease stage and histology. 4, 5 While these surgical treatments offers the potential for disease cure, they also result in the loss of future fertility in a reproductive-aged population.
Generally, the risk of occult corpus invasion is low in early-stage cervical cancer, and some argue that uterine preservation can be safe in this subset of young women. 6e9 However, in women whose tumors exhibit factors that may increase the risk of cancer metastasis and recurrence, such as lymphatic or vascular invasion, large tumor size, and specific histological subtypes, uterine corpus preservation is generally not recommended. 10e12 The National Comprehensive Cancer Network guidelines suggest that trachelectomy, the removal of the uterine cervix and adjacent tissues, may be a reasonable fertility-sparing treatment option for stage IA and IB1 (tumor size 2 cm) cervical cancer. 5 Uterine preservation should thus be considered "optional" after weighing risks and benefits of this treatment strategy. The utilization for trachelectomy among young women with early-stage cervical cancer has not yet been well examined. The objective of this study was to examine the trends, characteristics, and survival outcomes among young women with early-stage cervical cancer who underwent trachelectomy.
Materials and Methods

Study design and eligibility
The Surveillance, Epidemiology, and End Results (SEER) Program is a population-based tumor registry that is supported and managed by the National Cancer Institute in the United States. It includes data beginning in 1973, and covers 27.8% of the US population from 11 states and 7 areas. 13 It is both publicly available and deidentified, thus this study was deemed exempt by the University of Southern California and Tokai University institutional review boards. Registrars responsible for entering data into SEER are trained by the National Cancer Registrars Association to maintain rigorous quality control. SEER*Stat 8.3.5 (IMS Inc, Calverton, MD) was used to extract data from 1973 through 2014. Cases were identified within the category for "cervix uteri" and limited to malignancy. Within the extracted data set, stage I cervical cancer cases with known surgical procedure types from 1998 through 2014 were included in the study. Data from 1973 through 1997 were removed due to lack of detailed information regarding the surgical procedure. Eligible histologic types included squamous, adenocarcinoma, and adenosquamous. Other rare histology types such as small cell neuroendocrine tumors were excluded based on the National Comprehensive Cancer Network guideline recommendation. 5 Cervical sarcomas and metastatic tumors to the uterine cervix originating from other organs were also excluded, as were women who had received preoperative radiotherapy.
Clinical information
Variables extracted from the database included patient demographics, tumor information, treatment types, and survival outcomes. Patient demographics included age, year at diagnosis, race/ ethnicity, marital status, and registration area. Tumor information included cancer stage, histologic subtype, tumor differentiation grade, tumor size, and lymph node status. Treatment types included surgical treatment and postoperative treatment (radiotherapy and chemotherapy). Survival information included cause-specific survival and overall survival.
Study definitions
Recorded disease stage was reclassified based on the American Joint Committee on Cancer TNM 7th edition classification.
14 International Classification of Diseases for Oncology, 3rd Edition site/ histology validation list and World Health Organization histological classification were used for grouping histologic subtypes as shown in Supplemental Table 1 . 13 Women with a surgical code for trachelectomy were classified as having undergone trachelectomy, removal of cervical stump, and cervicectomy, while women with a surgical code for hysterectomy were categorized based on the type of hysterectomy that was introduced as "RX Summ-Surg Prim Site" in Supplemental Table 2 . Cases in which surgical codes did not specify the type of hysterectomy were classified as hysterectomy, not otherwise specified.
An age cutoff of <45 years was chosen to capture reproductive-age women based on previous work. 15 In this database, survival data were collected via linkage with state mortality records and the National Death Index. Cause-specific survival was defined as the time interval between the initial cervical cancer diagnosis and death due to cervical cancer, while overall survival was defined as the time interval between the initial cervical cancer diagnosis and death from any reason (all cause).
Statistical analysis
The primary objective of the analysis was to examine trends and characteristics associated with trachelectomy use. The secondary objective was to examine survival in women who underwent trachelectomy for cervical cancer. For these analyses, women who underwent trachelectomy were compared to those who underwent hysterectomy.
Continuous A binary logistic regression model was used for multivariable analysis to determine independent factors associated with trachelectomy use, and the magnitude of statistical significance was expressed as an odds ratio (OR) with 95% confidence interval (CI). In this model, patient demographics and tumor factors were entered in the final model. The Hosmer-Lemeshow test was used to assess the goodness-of-fit in the final model, and a P value of !.05 was considered a good-fit model. 16 The Joinpoint Regression Program (Version 4.6.0.0) provided by the National Cancer Institute was utilized for evaluating temporal trends of the proportion of women <45 years of age with stage IA and IB1 (tumor size 2 cm) cervical cancer who underwent trachelectomy. Time point data were examined every calendar year to identify temporal changes. The presence of annual trend was examined with a linear segmented regression test, and log transformation was performed to determine the annual percent change (APC) and 95% CI.
Survival analysis was performed to examine the association between trachelectomy and cause-specific/overall AJOG at a Glance Why was this study conducted? As fertility-sparing trachelectomy is a relatively new treatment modality for reproductive-age women with early-stage cervical cancer, utility and survival outcomes related to this procedure have not been well studied in a populationbased setting.
Key findings From 1998 through 2014, there was a significant increase in the utilization of trachelectomy reaching nearly 5% in recent years.
What does this add to what is known?
Women who underwent trachelectomy had comparable cervical cancer-specific survival (5-year rates: 96.9% vs 96.6%) and overall survival (96.1% vs 96.6%) to those who underwent hysterectomy.
Original Research GYNECOLOGY ajog.org survival. The Kaplan-Meier method was used to construct survival curves, and the statistical difference between the curves was compared with the log rank test. Survival estimate was examined using Cox proportional hazard regression models, and the magnitude of statistical significance was expressed with hazard ratios (HR) and 95% CI.
We performed propensity score matching as a validation measure when assessing survival following trachelectomy and hysterectomy by adjusting for background differences between the 2 treatment groups. The propensity score was determined by multivariable logistic regression analysis (trachelectomy vs hysterectomy). Patient demographics (age at cervical cancer diagnosis, ethnicity, marital status, registered area, and calendar year at cervical cancer diagnosis), tumor characteristics (stage, histology type, and grade), and treatment type (radiotherapy and chemotherapy) were entered in the propensity score model. An automated algorithm was used for one-to-one propensity score matching between the trachelectomy and hysterectomy groups. The optimal caliper width for estimating differences was equal to 0.2 of the SD for the logit of the propensity score, resulting in a propensity score difference cutoff of 0.01 in this study. 17 Standardized difference was determined after propensity score matching, and a value of 0.10 was considered to indicate good balance between the 2 groups. 18, 19 In a sensitivity analysis, a study population of only women with stage IA2 and IB1 ( 2 cm) cervical cancer who had pelvic lymphadenectomy was examined for trends, characteristics, and outcomes. This is based on the rationale that treatment recommendations for surgical modality (hysterectomy type and lymphadenectomy use) are largely different between stage IA1 disease and stage IA2eIB1 disease per the current guidelines. 5 The variance inflation factor was determined among covariates in the multivariable analysis, and a value of !2.0 was interpreted as multicollinearity. A P value of <.05 was considered statistically significant (2-tailed). Software (SPSS, Version 25.0; IBM Corp, Armonk, NY) was used for analyses. The Strengthening the Reporting of Observational Studies in Epidemiology guideline was consulted for outlining this study. 20 
Results
The patient selection criteria are shown in Figure 1 . Among 23,981 women with cervical cancer who underwent trachelectomy or hysterectomy, 6359 women were <45 years with stage IAe IB1 (tumor size 2 cm) cervical cancer. In all, 190 (3.0%; 95% CI, 2.6e3.4) underwent trachelectomy, and 6169 (97.0%) underwent hysterectomy. The characteristics associated with trachelectomy are shown in Table 1 .
The median age of the trachelectomy group was 31.0 (IQR, 28e34) years. Women who underwent trachelectomy were more often younger, of nonblack *Other than hysterectomy and trachelectomy; **other than squamous cell carcinoma (SCC), adenocarcinoma (AC), and adenosquamous carcinoma (AS) histology.
CxCA, cervical cancer; NOS, not otherwise specified. ajog.org race/ethnicity, had single marital status, and were more likely to be residents of the eastern United States (all, P < .05). They also more frequently had stage IB1 disease, nonsquamous cell carcinoma histology, and grade 2 tumors, with higher rates of lymphadenectomy compared to women who underwent hysterectomy (all, P < .05). The proportion of women who underwent trachelectomy in this study population was 1.2% from 1998 through 2002. This was followed by a 3.0% trachelectomy rate from 2003 through 2008. By the period of 2009 through 2014 it had reached nearly 5% (4.5%). From 1998 through 2014, there was a significant increase in the utilization of trachelectomy among women aged <45 years with early-stage cervical cancer (APC, 9.5%; 95% CI, 4.2e15.2; P < .001) (Figure 2, A) . The frequency of trachelectomy declined significantly with each additional age (APC, e11.0; 95% CI, e14.2 to e7.8; P < .001) (Figure 2, B Results of propensity score matching, based on the baseline characteristics of women in both treatment groups, are shown in Table 3 . Postmatching patient demographics, tumor characteristics, and treatment types were similar between the 2 groups (all, standardized difference 0.10). After propensity score matching, the trachelectomy group had an equivalent 5-year cause-specific survival rate (96.9% vs 96.6%; HR, 0.73; 95% CI, 0.23e2.30; P ¼ .59) (Figure 3 , A) and had a similar 5-year overall survival rate (96.1% vs 96.6%; HR, 0.76; 95% CI, 0.26e2.20; P ¼ .61) (Figure 3 , B) compared to the hysterectomy group.
A subgroup of 2778 women with stage IA2eIB1 ( 2 cm) cervical cancer who underwent pelvic lymphadenectomy was examined (Supplemental Tables 3  and 4) . Trachelectomy was performed in 137 of these women (4.9%; 95% CI, 4.1e5.7), and similar to the entire cohort, women in the trachelectomy After propensity score matching (Supplemental Table 5 ), the patient demographics were well balanced between the 2 groups. In this group of stage IA2eIB1 ( 2 cm) cervical cancer, causespecific survival (5-year rates: 96.6% vs 96.2%; HR, 0.68; 95% CI, 0.15e2.03; P ¼ .61), and overall survival (96.6% vs 94.8%; HR, 0.54; 95% CI, 0.13e2.26; P ¼ .39) were similar between the trachelectomy group and the hysterectomy group (Supplemental Figure) .
Comment
In recent years, approximately 1 in 20 women <45 years of age with stage IA or IB1 cervical cancer (tumor size is <2 cm in diameter) has undergone trachelectomy. This treatment was not associated with decreased cause-specific survival nor decreased overall survival among young women with early-stage cervical cancer when compared to hysterectomy.
Our study demonstrated an increasing trend in the utilization of trachelectomy in reproductive-aged women with earlystage cervical cancer. It is possible that this can be partially explained by the concurrent increasing age of first marriage and the number of unmarried women in the United States. 21 One recent study showed that the number of single women with cervical cancer has been substantially increasing despite a decreasing overall number of early-stage cervical cancer diagnoses among young women in the United States. 22, 23 Therefore, it is possible that there has been an increasing utilization for trachelectomy among reproductive-aged women with cervical cancer, for whom future fertility preservation is of great concern.
Another plausible explanation is that more women are choosing for various reasons to delay childbearing until later in life. The Centers for Disease Control and Prevention has identified a steady rise in the birth rate among women aged 35e39 and 40e44 years in recent years. 24, 25 This trend clearly implies that increasing numbers of women are choosing to delay childbearing until >35 years of age, resulting in increased opportunity to be diagnosed with cervical cancer.
Previous studies have shown that trachelectomy is safe and affords a good prognosis for women with stage IA2e IB1 lesions <2 cm in diameter. 26, 27 A systematic review in 485 women from 29 studies confirmed the safety of trachelectomy, as only 3.8% of women experienced recurrence and only 0.4% died during a median of 31.6 months of follow-up. 7 Our study also demonstrated that trachelectomy had equivalent survival compared to hysterectomy in the treatment of reproductive-aged women with early-stage cervical cancer. Thus, these results support recent evidence-based guidelines regarding the safety and feasibility of fertility-sparing Original Research GYNECOLOGY ajog.org treatment as a reasonable treatment option in this subset of young women. Despite good oncologic outcomes of fertility-sparing treatment in early-stage cervical cancer, individuals should be carefully selected and have a meticulous preoperative evaluation. 5 A limited number of studies have examined fertility-sparing treatment in women with stage IB1 cervical cancer with larger tumors ranging between 2e4 cm in diameter, and while they reported safe oncologic outcomes, more women in this subgroup required adjuvant therapy, which may consequently reduce fertility. 11,28e30 Therefore, trachelectomy is not commonly utilized in women with stage IB disease with a larger tumor size.
Additionally, close attention should be paid to the surgical approach for trachelectomy. A minimally invasive approach has been shown to reduce intraoperative blood loss, postoperative complications, and hospital stay compared to laparotomy. 31 However, a recent phase III randomized study reported higher recurrence rates and poorer survival in women who underwent minimally invasive radical hysterectomy compared to abdominal radical hysterectomy for early-stage cervical cancer. 32 As this study did not address surgical approach, and there is currently no other study that has examined this association, continued discussions and research regarding the optimal surgical approach for women undergoing radical trachelectomy is encouraged.
Given the relatively low mortality rates in young women with early-stage cervical cancer, the use of a large population-based sample was a particular strength of this study in examining trends, characteristics, and outcomes of trachelectomy. Propensity score matching additionally enhanced our analytic approach as patient demographics and tumor characteristics were largely different between the trachelectomy group and the hysterectomy group.
Our study is also clinically important because a randomized trial comparing the survival of trachelectomy and hysterectomy is not feasible for women who desire fertility preservation. Additionally, our study validated a recent population-based study using the National Cancer Instituteedesignated hospital data (National Cancer Database) that showed use of trachelectomy with early-stage cervical cancer has increased in the United States and that survival was similar between the trachelectomy and the hysterectomy group. 33 Similar survival results across the 2 different large data sets are reassuring that this surgical procedure for fertility-sparing treatment is safe.
We recognize a number of important limitations. First, we lack data on postoperative fertility outcomes. In a systematic review of 660 women who underwent abdominal radical trachelectomy, 235 women attempted pregnancy and 114 (49%) successfully conceived. 7, 34 These results are in contrast to another large retrospective study that reported a total of 61 pregnancies in 48 of 172 (28%) women who underwent abdominal trachelectomy. 35 In both studies, miscarriage, preterm labor, and stillbirth were prevalent. Thus, in addition to consideration of oncological outcomes, fertility and obstetric outcomes warrant additional discussion with patients to determine the most appropriate treatment modality on an individual basis.
A second limitation of this study is our inability to perform a complete risk adjustment given limitations in the types of data included in the SEER data set. Data regarding the surgical approach for trachelectomy (simple vs radical), route (abdominal, vaginal, or minimally invasive), presence or absence of lymphovascular space invasion in the tumor, details of postoperative chemotherapy administration, and postoperative hormonal function are not captured in the data set but are associated with the development of recurrent disease and overall survival. 7, 36 Likewise, no information for recurrence is captured in this database. While not included in this study, these factors are still an important part of decisions regarding treatment strategy in these young women with early-stage cervical cancer, and the rates of postchildbearing hysterectomy are not Original Research GYNECOLOGY ajog.org
